UBA52 and cholangiocarcinoma: EdU assay results revealed that a decrease in ROCK2 levels reduced the proliferation of drug-resistant CCA cells treated with Pemigatinib, whereas UBA52-knockdown restored the proliferative capacity of these drug-resistant cells (Fig. 7C and S12D–F).